Form D · Other Technology
Comet Therapeutics, Inc.
Cambridge, MA · CIK 0001779596
Offering snapshot reported Jun 13, 2019 · SEC filing
- Reported sold
- $14.1M Offering amount: $14.1M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 6, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 13, 2019 | Initial | $14,053,001 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-341864
Source: Form D, filed Jun 13, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lucas De Breed | Director |
| David De Graaf, Ph.D. | Director, Executive |
| Enej Kuscer, Ph.D. | Executive |
| Bernardus Machielse | Director |
| Henrijette Richter, Ph.D. | Director |
| Art Taveras, Ph.D. | Executive |
| Peter Van Vlasselaer, Ph.D. | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
610 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139